Blood Testing for Muscle Aches in Patients Taking Crestor (Rosuvastatin)
When a patient on Crestor reports muscle aches, immediately order a creatine kinase (CK) level and thyroid-stimulating hormone (TSH) test. 1, 2
Essential Initial Laboratory Tests
Creatine Kinase (CK)
- CK is the primary test to evaluate statin-associated muscle symptoms and should be obtained immediately when muscle pain, tenderness, or weakness is reported 1, 3
- Compare the result to any baseline CK level obtained before starting Crestor, as asymptomatic CK elevations are common and pre-treatment knowledge aids clinical decision-making 1
- The FDA label for Crestor specifically instructs to call your healthcare professional for unexplained muscle pain, tenderness, or weakness, which triggers CK measurement 2
Thyroid-Stimulating Hormone (TSH)
- TSH should be obtained in any patient with muscle symptoms because hypothyroidism predisposes to myopathy and can mimic statin-related muscle problems 1, 3
- Thyroid problems are specifically listed in the Crestor label as a condition that increases risk for muscle problems 2
Interpreting CK Results and Clinical Action
CK < 3× Upper Limit of Normal (ULN)
- Continue Crestor at the current dose if symptoms are mild 1
- Rule out common non-drug causes such as recent exercise or strenuous work 1, 4
- Monitor symptoms and consider repeat CK in 4-6 weeks if symptoms persist 4
CK 3-10× ULN
- Follow symptoms and CK levels weekly until there is no longer medical concern 1
- If symptoms are progressive or worsening, consider dose reduction or temporary discontinuation 1, 3
- Patients with moderate CK elevations can usually continue statins with careful monitoring if asymptomatic 1
CK > 10× ULN with Muscle Symptoms
- Discontinue Crestor immediately 1, 2
- This represents potential myopathy or early rhabdomyolysis requiring urgent intervention 1, 3
- Wait for symptoms to resolve and CK to normalize before considering rechallenge with a lower dose 1
Additional Laboratory Monitoring
Liver Function Tests
- While not the primary test for muscle symptoms, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be checked as part of comprehensive statin monitoring 1
- The ACC/AHA guideline recommends baseline liver function measurements, though this is debated 1
- Modest transaminase elevations (<3× ULN) do not contraindicate continuing therapy with careful monitoring 1
Urinalysis
- Consider checking for myoglobinuria if CK is significantly elevated, as this indicates rhabdomyolysis risk 2
- The Crestor label mentions dipstick-positive proteinuria as a potential finding, though not specifically related to muscle symptoms 2
Critical Risk Factors to Assess
When evaluating muscle symptoms, document these high-risk features that increase myopathy risk:
- Advanced age (especially >80 years), with women at higher risk than men 1
- Small body frame and frailty 1
- Renal insufficiency, especially due to diabetes 1, 2
- Concomitant medications that interact with statins, particularly CYP3A4 inhibitors 1, 2
- Higher statin doses (40 mg rosuvastatin carries greater risk than lower doses) 1, 5
Common Pitfalls to Avoid
- Do not perform routine CK monitoring in asymptomatic patients—it is not recommended and provides little clinical value 1, 4
- Do not ignore mild symptoms with normal CK; statin-associated muscle symptoms can occur without CK elevation 3
- Do not overlook baseline CK values; knowing pre-treatment levels is essential for interpreting subsequent changes 1, 4
- Do not forget to assess for recent strenuous exercise, the most common non-drug cause of transient CK elevation 1, 4
- Do not continue Crestor if CK exceeds 10× ULN with symptoms; this mandates immediate discontinuation 1, 2